katherine

Zytiga 250mg tablet: Abiraterone Price & Side effects | Myapplepharma

Abiraterone is sold under brand name Zytiga
Zytiga 250mg is belongs to type of anti-cancer medication that will act by decline the androgen production in the body.
Androgen is a male hormone that can maintance the tumor cell in prostate glands.
Actually this drug is given by co administration with prednisolone, a steroid which reduce the liability of side effects produced by Abiraterone.

**Zytiga 250mg** , **Zytiga 250mg tablet**

DOSAGE

The prescribed dose of Zytiga 250mg is initial as 4 tablets given orally once daily.
The drug Zytiga 250mg tablet administrated combination with 5mg prednisolone twice daily in empty stomach.
Zytiga 250mg tablet given on an empty stomach.
Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Zytiga Tablets is taken.
Swallowed whole with water.
Chew the tablets or Do not crush

MECHANISM OF ACTION

Androgens are balance the production of malignant in prostate.
Zytigais belongs to anti androgen drugs, that causes to suppress the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is involves in androgen conglomerate.
Reduce the serum testosterone level.
Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Zytiga 250mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine
Half-life of tablet Zytiga 250mg is 12 ± 5 hours.

SAFETY AND WARNING

Any allergy, serious liver problem or pregnant in patient, Zytiga 250mg therapy should be stopped
Avoid taking of other medications, i.e prescription, over-the-counter, vitamins, herbal remedies, etc be sure to inform the doctors before the treatment.
Do not take Aspirin administrated and products containing aspirin till doctor particularly allow the drug.

OVERDOSAGE:

Zytiga 250mg has no essential antidote, If overdose occurs end treatment with the drug and give general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function

DRUG INTERACTION

Interaction of Zytiga 250mg with dextromethorphan will raises the Cmax and AUC of dextromethorphan
Interaction Zytiga 250mg with strong CYP3A inhibitors or inducers , concomitant use with caution because pharmacokinetics is not evaluated.

STORAGE

The drug stored at 15℃ – 30℃
Keep the drug in dry place.

MISSED DOSE

If patient missed the dose of Zytiga 250mg , that missed dose will be skipped and follow the regular dosing schedule.

SIDE EFFECTS

Common effects :

Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency, Hepatotoxicity, Hypertension, Decrease in ka level, Adrenocortical insufficiency
Musculo skeletal and Connective tissue disorders:Joint swelling, discomfort, muscle discomfort
General Disorder: Oedema
Cardiac disorders: Hot flush, hypertension, arrhythmias, chest pain, cardiac failure
GIT disorders: Diarrhea, dyspepsia
Infections and Infestation:UTI
Pulmonary disorder: Cough
Renal:Urinary frequency, nocturia
Injuries: Fractures.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/abiraterone-250mg.php

https://myapplepharma.com/abiraterone.php

ZELGOR 250MG TABLET (Abiraterone acetate)

Abiraterone acetate is sold under brand name Zelgor. Zelgor 250mg is belongs to type of anti-cancer medication that will act by decline the androgen production in the body. Androgen is a male hormone that canmaintained the tumor cell in prostate glands, the main ingredient which is used as Abiraterone. Actually this drug is given by co administration with prednisolone, a steroid which reduce the liability of side effects produced by Abiraterone.

**Zelgor 250mg ,** **Zelgor 250mg tablet**

DOSAGE AND ADMINISTRATION

The prescribed dose of Zelgor 250mg is initial as 4 tablets given orally once daily. The drug Zelgor administrated combination with 5mg prednisolone twice daily in empty stomach. Zelgor 250mg tablet given on an empty stomach. Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Zelgor 250mg tablet is taken. Swallowed whole with water. Chew the tablets or Do not crush.

MECHANISM OF ACTION

Androgens are balance the production of malignant in prostate. Zelgor is belongs to anti androgen drugs, that causes to suppress the enzyme17α-hydroxylase C 17, 20-lyase (CYP17), it is involves in androgen conglomerate. Reduce the serum testosterone level. Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Zelgor 250mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine Half-life of Zelgor 250mg tablet is 12 ± 5 hours.

DRUG INTERACTION

Interaction of Zelgor 250mg with dextromethorphan will raises the Cmax and AUC of dextromethorphan Interaction Zelgor 250mg with strong CYP3A inhibitors or inducers , concomitant use with caution because pharmacokinetics is not evaluated.

SAFETY

Any allergy, serious liver problem or pregnant in patient, Zelgor 250mg therapy should be stopped Avoid taking of other medications, i.e prescription, over-the-counter, vitamins, herbal remedies, etc be sure to inform the doctors before the treatment. Do not take Aspirin administrated and products containing aspirin till doctor particularly allow the drug.

OVERDOSAGE

Zelgor has no essential antidote, If overdose occurs end treatment with the drug and give general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.

MISSED DOSE

If patient missed the dose of Zelgor 250mg , that missed dose will be skipped and follow the regular dosing schedule.

SIDE EFFECTS

Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency, Hepatotoxicity, Hypertension, Decrease in ka level, Adrenocortical insufficiency Musculo skeletal and Connective tissue disorders:Joint swelling, discomfort, muscle discomfort General Disorder: Oedema Cardiac disorders: Hot flush, hypertension, arrhythmias, chest pain, cardiac failure GIT disorders: Diarrhea, dyspepsia Infections and Infestation:UTI Pulmonary disorder: Cough Renal:Urinary frequency, nocturia Injuries: Fractures

STORAGE

The drug stored at 15℃-30℃. Keep the drug in dry place.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/zecyte-500mg.php
https://myapplepharma.com/abiraterone.php

Zelgor 500mg tablet

Abiraterone is sold under brand name Zelgor 500mg.
Zelgor 500mg is belongs to type of anti-cancer medication that will act by decline the androgen production in the body.
Androgen is a male hormone that can maintained the tumor cell in prostate glands.
This drug is given by co administration with prednisolone, a steroid which reduce the liability of side effects produced by Abiraterone .

DOSAGE

The prescribed dose of Zelgor is initial as 4 tablets given orally once daily.

The drug Zelgor 500mg administrated combination with 5mg prednisolone twice daily in empty stomach.

Zelgor 500mg tablet given on an empty stomach.
Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Zelgor 500mg tablet is taken.
Swallowed whole with water.
Chew the tablets or Do not crush

MECHANISM OF ACTION

Androgens are balance the production of malignant in prostate.
Zelgor 500mg belongs to anti androgen drugs, that causes to suppress the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is involving in androgen conglomerate.
Reduce the serum testosterone level.
Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Zelgor 500mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine
Half-life of Zelgor 500mg tablet is 12 ± 5 hours.

SAFETY AND WARNING

Any allergy, serious liver problem or pregnant in patient, Zelgor 500mg therapy should be stopped Avoid taking of other medications, i.e. prescription, over-the-counter, vitamins, herbal remedies, etc. be sure to inform the doctors before the treatment.
Do not take Aspirin administrated and products containing aspirin till doctor particularly allow the drug.

DRUG INTERACTION

Interaction of Zelgor 500mg with dextromethorphan will raises the Cmax and AUC of dextromethorphan Interaction Zelgor 500mg tablet with strong CYP3A inhibitors or inducers, concomitant use with caution because pharmacokinetics is not evaluated.

STORAGE

The drug stored at 15℃-30℃ Keep the drug in dry place.

MISSED DOSE

If patient missed the dose of Zelgor 500mg , that missed dose will be skipped and follow the regular dosing schedule.

SIDE EFFECTS

Common effects :

Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency, Hepatotoxicity, Hypertension, Decrease in ka level, Adrenocortical insufficiency Muscular skeletal and Connective tissue disorders: Joint swelling, discomfort, muscle discomfort
General Disorder: Edema
Cardiac disorders: Hot flush, hypertension, arrhythmias, chest pain, cardiac failure
GIT disorders: Diarrhea, dyspepsia
Infections and Infestation: UTI
Pulmonary disorder: Cough
Renal: Urinary frequency, nocturia
Injuries: Fractures.

OVERDOSAGE

Zelgor 500mg has no essential antidote, If overdose occurs end treatment with the drug and give general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/zelgor-500mg.php

https://myapplepharma.com/abiraterone.php

Zecyte 500mg tablet |Abiraterone acetate | apple pharmaceuticals

Abiraterone is sold under brand name Zecyte 500mg.
Zecyte 500mg tablet is belongs to type of anti-cancer medication that will act by decline the androgen production in the body.
Androgen is a male hormone that can maintained the tumor cell in prostate glands.
This drug is given by co administration with prednisolone, a steroid which reduce the liability of side effects produced by Abiraterone.

**Zecyte 500mg ,** **Zecyte 500mg tablet**

DOSAGE

The prescribed dose of Zecyte is initial as 4 tablets given orally once daily.

The drug Zecyte 500mg administrated combination with 5mg prednisolone twice daily in empty stomach.

Zecyte 500mg tablet given on an empty stomach.
Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Zecyte Tablets is taken.
Swallowed whole with water.
Chew the tablets or Do not crush

MECHANISM OF ACTION

Androgens are balance the production of malignant in prostate.
Zecyte 500mg belongs to anti androgen drugs, that causes to suppress the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is involving in androgen conglomerate.
Reduce the serum testosterone level.
Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Zecyte 500mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine
Half-life of tablet Zecyte 500mg is 12 ± 5 hours.

SAFETY AND WARNING

Any allergy, serious liver problem or pregnant in patient, Zecyte 500mg therapy should be stopped Avoid taking of other medications, i.e. prescription, over-the-counter, vitamins, herbal remedies, etc. be sure to inform the doctors before the treatment.
Do not take Aspirin administrated and products containing aspirin till doctor particularly allow the drug.

DRUG INTERACTION

Interaction of Zecyte 500mg with dextromethorphan will raises the Cmax and AUC of dextromethorphan Interaction Zecyte 500mg tablet with strong CYP3A inhibitors or inducers, concomitant use with caution because pharmacokinetics is not evaluated.

STORAGE

The drug stored at 15℃-30℃ Keep the drug in dry place.

MISSED DOSE

If patient missed the dose of Zecyte 500mg tablet , that missed dose will be skipped and follow the regular dosing schedule.

SIDE EFFECTS

Common effects:

Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency, Hepatotoxicity, Hypertension, Decrease in ka level, Adrenocortical insufficiency Muscular skeletal and Connective tissue disorders: Joint swelling, discomfort, muscle discomfort
General Disorder: Edema
Cardiac disorders: Hot flush, hypertension, arrhythmias, chest pain, cardiac failure
GIT disorders: Diarrhea, dyspepsia
Infections and Infestation: UTI
Pulmonary disorder: Cough
Renal: Urinary frequency, nocturia
Injuries: Fractures.

OVERDOSAGE

Zecyte 500mg tablet has no essential antidote, If overdose occurs end treatment with the drug and give general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/zecyte-500mg.php

https://myapplepharma.com/abiraterone.php

Zecyte 250MG TABLET (Abiraterone acetate) | Apple pharmaceuticals

Zecyte 250mg is known as fluoropyrimidine carbamat who having the anti-cancer activity. The drug supplied as oblong and film coated tablet for oral administration, the main ingredient which is used as Abiraterone . Zecyte is a systemic prodrug of 5’-deoxy-5-fluorouridine (5’-DFUR) which is changed to 5 fluoro uracil Zecyte 250mg is also have anti-metabolite activity and the activity of Zecyte tablet will inhibits the growth of tumor cells and slows their spread in the body. Zecyte is prescription drugs sold under the proper guidance of medical oncologist and pharmacist.

Monotherapy:First line therapy of patients with advanced colorectal cancer:

The usual dose of Zecyte 250mg tablet is 1250mg/m2 should be taken orally as twice daily (morning and evening dose 2250MG/m2); therapy continue for 2 weeks followed by 1 week rest period given as 3 weeks cycle

Adjuvant therapy for Duke’s colon cancer:The usual dose of Zecyte 250mg is 1250mg/m2 orally as twice daily (morning and evening dose 2250MG/m2); for 2 weeks followed by 1 week given as 3 weeks for total 8 cycles (24 weeks)

Breast cancer

Monotherapy: Recommended dose: 1250mg/m2 should be taken as orally for twice daily In combination with docetaxel; 1250mg/m2 of Zecyte with 75mg/m2 of docetaxel for 3 weeks After a meal the drug Zecyte 250mg tablet should be given within 30 minutes

In pediatric

The safety and efficacy of the Zecyte 250mg tablet in pediatric patients has not been established

PHARMACOKINETIC

Absorption:

The time to peak plasma level at about 1.5 hours Food reduced both the rate and duration of absorption of Zecyte with mean Cmax and AUC0-∞ reduced by 60% and 35% respectively

Distribution:

The human plasma protein bound to Zecyte 250mg is occurs in less than 60%

Bio-activation and metabolism:

Zecyte is largely metabolized to 5-FU enzymatically. In liver, 60 kDa carboxylesterase hydrolyses to 5’-deoxy-5-fluorocytidine. An enzyme which converts 5’-DFCR to 5’-DFUR known as Cytidine deaminase. another an enzyme which involved in the conversion of 5’-DFUR to 5-FU active drug is Thymidine phosphorylase

Excretion:

The route of elimination of Zecyte 250mg is occurred through urine 95.5% The mean terminal half life period of Zecyte is 0.75 hour

MECHANISM OF ACTION

Enzymes changes capecitabine to 5-fluorouracil (5-FU) in vivo. Both normal and cancer cells metabolize 5-FU to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP) and 5-fluorouridine triphosphate (FUTP). These metabolites leads to cell damage by two different mechanisms. First, FdUMP and the folate cofactor, N5-10-methylenetetrahydrofolate, link to thymidylate synthase (TS) and form a complex of covalently bound ternary. This bounding prohibits the thymidylate from 2’-deoxyuridylate formation. Thymidylate is the required precursor of thymidine triphosphate, which is specifically used for the synthesis of DNA, so that a inadequacy of this mixture can prevent cell division. Second, during the synthesis of RNA the nuclear transcriptional enzymes can mistakenly fused FUTP in place of uridine triphosphate (UTP). This metabolic error can prevent RNA processing and synthesis of protein.

PRECAUTION AND WARNING

Cardio toxicity: while taking Zecyte 250mg , cardio toxicity occurs like; myocardial infarction, angina, dyshythmias, cardiac arrest sudden death, Cardiomyopathy Diarrhea: patients with severe diarrhea should be monitored Dihydropyrimidine dehydrogenase deficiency Dehydration and renal failure Embryo fetal toxicity Mucocutaneous and dermatologic toxicity Hyperbilirubinaemia Hematological problems Care should be taken while using in geriatric patients Hepatic insufficiency Coagulopathy: concomitant with warfarin, anti-coagulant response should be monitored

DRUG INTERACTION

Zecyte 250mg interaction with warfarin and phenprocoumon, bleeding occurs. These events occurred within several days and even a month also Interaction of phenytoin with Zecyte 250mg , toxicity related to elevation of phenytoin levels Concomitant use of Leucovorin: the toxicity and concentration of 5-FU increased by Leucovorin. In elderly patients, phenytoin and Leucovorin is administered weekly which may cause; diarrhea, dehydration, enterocolitis which may causes death. other than warfarin, there is no drug interaction occurs while concomitant with CYP2C9 substrates While combination of Zecyte with CYP2C9 substrates Care should be taken

DRUG-FOOD INTERACTION

In case of administering Zecyte with food, it leads to reduce the rate and duration of absorption of Zecyte 250mg . Zecyte (Abiraterone) tablets should be administered within 30 minutes after food

CONTRAINDICATION

Renal impairment patients.Patients with hypersensitivity to Zecyte 250mg tablet or other components.

MISSED DOSE

If dose is missed then take the dose of Zecyte 250mg , must consult with medical oncologist and follow the suggestions Avoid taking self medicate. Or missed dose must be skipped and continue the regular dosing schedule Do not double the dose

SIDE EFFECTS

Most common side effects : Diarrhea, nausea, anemia, Lymphopenia, head and foot syndrome, edema, fatigue, fever, headache, pain, paresthesia, alopecia, dermatitis, abdominal pain, anorexia, loss of appetite, constipation, dyspepsia, stomatitis, vomiting, neutropenia, thrombocytopenia, dyspnea, bilirubin decreased, eye irritation

Common side effects : Dermatitis , rash, dizziness, headache, Chest pain, weakness, dehydration, dry mouth, dyspepsia, Pruritus, taste disturbance, back pain Post marketing reports: Toxic leukoencephalopathy

STORAGE

Zecyte 250mg should be stored at 20℃ to 25℃ (68℉ to 77℉)

PREGNANCY

Pregnancy category: D Zecyte 250mg may cause harm to the fetus. Generally Zecyte should not be recommended in pregnancy or women who are become pregnant

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/zecyte-250mg.php

https://myapplepharma.com/abiraterone.php

Hertraz 150mg injection online – Trastuzumab| Myapplepharma

Hertraz 150mg is a group of medicines which belongs to anti neoplastic medication. Hertraz 150mg is a chemotherapy drug. It is recommended that Hertraz 150mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

USES

The Hertraz 150mg injection is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

WORK AS

Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.
Hertraz acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Hertraz can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.
The Hertraz 150mg injection should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine

Adjuvant treatment, breast cancer:

The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:

During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV (intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Hertraz dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.

The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:

For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.

Metastatic Treatment, Breast Cancer:

Hertraz 150mg administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development. Metastatic Gastric Cancer:
Hertraz 150mg injection administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.

Embryo fetal damage

Hertraz 150mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment.

Cardiomyopathy

Patient getting Hertraz 150mg have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuing.

Pulmonary toxicity

Some serious fatal cases of pulmonary toxicity occur during Hertraz 150mg treatment.

Infusion reactions

During Hertraz 150mg treatment some life-threatening infusion reactions are produced. In serious infusion reactions, Stop the Hertraz 150mg treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Hertraz treatment. Use with Caution.

Therapy induced neutropenia

Higher incidence of neutropenia occurs during Hertraz 150mg treatment.

DRUG INTERACTION

In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Hertraz 150mg treatment.
Hertraz 150mg injection interaction with anthracycline after ending of Hertraz 150mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.

CONTRAINDICATION

Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hertraz 150mg injection, Hence Hypersensitivity reactions are occurring.

STORAGE

Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hertraz 150mg diluted bag at 2℃ to 8℃ for 24 hours.

MISSED DOSE

The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.

SIDE EFFECTS

Common side effects:

Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain

Serious side effects:

Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/hertraz-150mg.php

https://myapplepharma.com/trastuzumab.php

Trastuzumab – Hermab 440mg injection online | Myapplepharma

Hermab 440mg is a group of medicines which belongs to anti neoplastic medication. Hermab 440mg is a chemotherapy drug. It is recommended that Hermab 440mg be administered under the guidance of a qualified physician experienced in the use of cancer chemotherapeutic agents.

USES

The Hermab 440mg injection is used alone or combination with other medicine for the treatment in patients who suffering from metastatic breast cancer.
The drug also indicated with combination of other medicine for the treatment of certain types of stomach or esophagus cancer in some persons.

WORK AS

Different type of breast cancer cells has a higher than normal level of a protein called HER2 (human epidermal growth factor receptor 2) on their surface. These HER2 receptors get signals which stimulate the tumor cells to develop and reproduce. But breast cancer cells with too many HER2 receptors can Choice too many growth signals and so start developing and proliferating too much and too fast.
Hermab acts by adhere itself to the HER2 receptors on the surface of breast cancer cells and stopping them from collecting growth signals. By stopping the signals, Hermab can slow or inhibit the growth of the breast cancer and the drug is an immune targeted therapy. In addition to inhibiting HER2 receptors, Trastuzumab can also help to fight against breast cancer by attentive the immune system to damage the cancer cells onto which it is attached.
The injection Hermab should not mix with other drugs and do not administer as an intravenous push or bolus.
Trastuzumab should not be substitute for or with ado-Trastuzumab emtansine

Adjuvant treatment, breast cancer:

The drug given according to one of the following doses and schedules for a 52 weeks total of trastuzumab treatment:
During combination with paclitaxel, docetaxel, or docetaxel /Carboplatin:
Starting dose of 4 mg/kg as an IV (intravenous infusion) over 90 minutes followed at 2 mg/kg as an IV(intravenous infusion) over 30 minutes weekly during treatment of chemotherapy given with paclitaxel or docetaxel for first 12 weeks or 18 weeks (docetaxel/carboplatin) The Hermab dose for One week following the last weekly administers Trastuzumab at 6 mg/kg as an IV (intravenous infusion) over 30 to 90 minutes every three weeks.

The injection given as a single agent within three weeks following completion of multi-modality, anthracycline-based chemotherapy regimens:
For an intravenous infusion over 90 minutes: Initial dose at 8 mg/kg
Successive doses at 6 mg/kg over 30 to 90 minutes every three weeks as an intravenous infusion.
Adjuvant treatment stretching beyond one year is not recommended.
Metastatic Treatment, Breast Cancer:
Hermab administrated alone or in combination with paclitaxel, at a starting dose of 4 mg/kg as a 90-minute intravenous infusion continued by successive once weekly doses of 2 mg/kg as 30-minute intravenous infusions until disease development.
Metastatic Gastric Cancer:
Hermab administrated at a starting dose of 8 mg/kg as a 90-minute IV intravenous infusion continued by successive doses of 6 mg/kg as an intravenous infusion over 30 to 90 minutes every three weeks until disease development.

Embryo fetal damage

Hermab 440mg is contraindicated to pregnancy period. Avoid becoming pregnancy during this therapy. Use efficient contraceptives during treatment

Cardiomyopathy

Patient getting Hermab 440mg injection have increased risk of exposing to cardiac disorders. Provide alternative therapy management In serious condition, treatment should be discontinuing

Pulmonary toxicity

Some serious fatal cases of pulmonary toxicity occur during Hermab 440mg treatment.

Infusion reactions

During Hermab 440mg treatment some life-threatening infusion reactions are produced. In serious infusion reactions, Stop the Hermab 440mg treatment permanently. Patient should be treated with premedication before starting the infusion to overcome the such problem, During Hermab 440mg treatment. Use with Caution.

Therapy induced neutropenia

Higher incidence of neutropenia occurs during Hermab 440mg treatment.

DRUG INTERACTION

In some phenomenal condition, patient should get anthracycline, in that situation patient’s cardiac function should be checked carefully with regular intervals.
Do not take anthracycline treatment for 7 months after stopping the Hermab 440mg treatment.
Hermab 440mg interaction with anthracycline after ending of Hermab 440mg treatment may have a chance of getting cardiac problem. This side effects occur because of Trastuzumab great disaster period is depends on population PK analysis.

CONTRAINDICATION

Probably no contraindicated occurs. The patients are contraindicated to the component present in the Hermab 440mg, Hence Hypersensitivity reactions are occurring.

STORAGE

Store the drug at 2℃ to 8℃ (refrigerator temperature) Protected the vial away from heat & light Stored at 2℃ to 8℃ for 28 days after reconstitution Stored Hermab 440mg diluted bag at 2℃ to 8℃ for 24 hours.

MISSED DOSE

The drug Missing doses can decrease their usefulness and raises the probability of developing drug resistance, that makes this drug lose their potency. For best results, it is important to accept each scheduled dose of Trastuzumab medication as instructed. If you miss a dose, leave the missed dose and continue with your regular dosing schedule. Do not have two doses to make up for a missed one. If you are not sure about what to do after missing a dose, the take advice with doctor or pharmacist.

SIDE EFFECTS

Common side effects:

Redness at injection site (IV)
Muscle/joint/back pain
Insomnia
Tiredness
Mild skin rash
Stuffy nose
Sinus pain

Serious side effects:

Increased coughing
Sudden unexplained weight gain
Unusual tiredness
Easy bruising or bleeding
Fast or pounding heartbeat
Increased coughing

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website : https://myapplepharma.com/hermab-440mg.php

https://myapplepharma.com/trastuzumab.php

Zytiga 250mg tableta

Abiraterona se vende bajo la marca Zytiga
Zytiga 250mg pertenece al tipo de medicamento contra el cáncer que actuará disminuyendo la producción de andrógenos en el cuerpo. El andrógeno es una hormona masculina que puede mantener la célula tumoral en las glándulas prostáticas.
En realidad, este medicamento se administra por administración conjunta con prednisolona, un esteroide que reduce la responsabilidad de los efectos secundarios producidos por la abiraterona .

DOSIS

La dosis prescrita de Zytiga 250mg es inicial como 4 tabletas administradas por vía oral una vez al día.
El medicamento Zytiga 250mg tableta administrado en combinación con 5 mg de prednisolona dos veces al día en estómago vacío.
Zytiga 250mg tableta administrado con el estómago vacío.
Los alimentos no deben tomarse durante al menos 2 horas antes y al menos 1 hora después de tomar la dosis de Zytiga tablets.
Tragado entero con agua.
Mastique las tabletas o no triture

MECANISMO DE ACCIÓN

Los andrógenos equilibran la producción de malignos en la próstata.
Zytigais pertenece a los medicamentos antiandrógenos, que hace que se suprima la enzima 17α-hidroxilasa C 17, 20-liasa (CYP17), está implicada en el conglomerado de andrógenos.
Reduce el nivel de testosterona en suero.
Disminución de la célula tumoral se produjo.

FARMACOCINÉTICA

Absorción:

El tiempo hasta la concentración plasmática máxima de la Zytiga 250mg tableta toma 12 horas.

Distribución:

Máximo unido a la proteína plasmática humana como la albúmina y la glicoproteína ácida alfa-1.

Metabolismo:

Los dos metabolitos principales de la abiraterona en el plasma humano son el sulfato de abiraterona y el sulfato de abiraterona N-óxido.

Excreción:

El fármaco se excreta principalmente en 88% de heces y 5% en orina.
La vida media de la tableta de Zytiga 250mg es de 12 ± 5 horas.

SEGURIDAD Y ADVERTENCIA

Cualquier alergia, problema hepático grave o embarazada en la paciente, se debe tratamiento con Zytiga 250mg
Evite tomar otros medicamentos, es decir, medicamentos recetados, de venta libre, vitaminas, remedios herbales, etc. Asegúrese de informar a los médicos antes del tratamiento.
No tome aspirina administrada y productos que contengan aspirina hasta que el médico lo permita particularmente

Sobredosis:

Zytiga 250mg no tiene antídoto esencial. Si se produce una sobredosis, finalice el tratamiento con el medicamento y brinde medidas de apoyo generales, como el control de las arritmias y la insuficiencia cardíaca, y evalúe la función hepática.

LA INTERACCIÓN DE DROGAS

La interacción de Zytiga 250mg con dextrometorfano elevará la Cmáx y el AUC de dextrometorfano
Interacción Zytiga 250mg con inhibidores o inductores potentes de CYP3A, uso concomitante con precaución porque no se evalúa la farmacocinética.

ALMACENAMIENTO

La droga almacenada a 15 ℃ – 30 ℃
Mantenga la droga en un lugar seco.

DOSIS PERDIDA

Si el paciente omitió la dosis de Zytiga 250mg , esa dosis omitida se omitirá y seguirá el programa de dosificación regular.

EFECTOS SECUNDARIOS

Efectos comunes:

Fatiga, artralgia, hipertensión, náuseas, edema, hipocalemia, diarrea, vómitos, tos, dolor de cabeza, deficiencia de glucocorticoides, deficiencia de corticoides minerales, hepatotoxicidad, hipertensión, disminución del nivel de ka, insuficiencia adrenocortical
Trastornos musculoesqueléticos y del tejido conectivo: inflamación articular, molestias, molestias musculares
Trastorno general: edema
Trastornos cardíacos: sofocos, hipertensión, arritmias, dolor torácico, insuficiencia cardíaca
Trastornos GIT: diarrea, dispepsia
Infecciones e infestaciones: ITU
Trastorno pulmonar: tos
Renal: frecuencia urinaria, nocturia
Lesiones: fracturas.

DETALLES DE CONTACTO

Teléfono: 9987711567

Correo electrónico: applepharmaceutical@gmail.com

Correo electrónico: info@myapplepharma.com

Sitio web: https://myapplepharma.com/abiraterone-250mg.php

https://myapplepharma.com/abiraterone.php

Zecyte 500mg Tableta| Acetato de abiraterona | productos farmacéuticos de manzana

Abiraterona se vende bajo la marca Zecyte 500mg .
Zecyte 500mg tableta pertenece al tipo de medicamento contra el cáncer que actuará disminuyendo la producción de andrógenos en el cuerpo.
El andrógeno es una hormona masculina que puede mantener la célula tumoral en las glándulas prostáticas.
Este medicamento se administra por administración conjunta con prednisolona, un esteroide que reduce la responsabilidad de los efectos secundarios producidos por la abiraterona .

**Zecyte 500mg** **, Zecyte 500mg tableta**

DOSIS

La dosis prescrita de Zecyte es inicial como 4 tabletas administradas por vía oral una vez al día.

El medicamento Zecyte 500mg administrado en combinación con 5mg de prednisolona dos veces al día en estómago vacío.

Zecyte 500mg tableta administrado con el estómago vacío.
Los alimentos no deben tomarse durante al menos 2 horas antes y al menos 1 hora después de tomar la dosis de Zecyte Tablets.
Tragado entero con agua.
Mastique las tabletas o no triture

MECANISMO DE ACCIÓN

Los andrógenos equilibran la producción de malignos en la próstata.
Zecyte 500mg pertenece a medicamentos antiandrógenos, que hace que se suprima la enzima 17α-hidroxilasa C 17, 20-liasa (CYP17), está involucrada en el conglomerado de andrógenos.
Reduce el nivel de testosterona en suero.
Disminución de la célula tumoral se produjo.

FARMACOCINÉTICA

Absorción:

El tiempo hasta la concentración plasmática máxima de la Zecyte 500mg tableta toma 12 horas.

Distribución:

Máximo unido a la proteína plasmática humana como la albúmina y la glicoproteína ácida alfa-1.

Metabolismo:

Los dos metabolitos principales de la abiraterona en el plasma humano son el sulfato de abiraterona y el sulfato de abiraterona N-óxido.

Excreción:

El fármaco se excreta principalmente en 88% de heces y 5% en orina.
La vida media de la tableta Zecyte 500mg es de 12 ± 5 horas.

SEGURIDAD Y ADVERTENCIA

Cualquier alergia, problema hepático grave o embarazo en la paciente, debe interrumpirse el tratamiento con Zecyte 500mg. Evite tomar otros medicamentos, es decir, medicamentos recetados, de venta libre, vitaminas, remedios herbales, etc. Asegúrese de informar a los médicos antes del tratamiento.
No tome aspirina administrada y productos que contengan aspirina hasta que el médico lo permita particularmente

LA INTERACCIÓN DE DROGAS

La interacción de Zecyte 500mg con dextrometorfano elevará la Cmax y el AUC de la interacción dextrometorfano Zecyte 500mg tableta con inhibidores o inductores potentes de CYP3A, uso concomitante con precaución porque no se evalúa la farmacocinética.

ALMACENAMIENTO

El medicamento almacenado a 15 ℃ -30 ℃ Mantenga el medicamento en un lugar seco.

DOSIS PERDIDA

Si el paciente omitió la dosis de la Zecyte 500mg tableta , esa dosis omitida se omitirá y seguirá el programa de dosificación regular.

EFECTOS SECUNDARIOS

Efectos comunes:

Fatiga, artralgia, hipertensión, náuseas, edema, hipocalemia, diarrea, vómitos, tos, dolor de cabeza, deficiencia de glucocorticoides, deficiencia de corticoides minerales, hepatotoxicidad, hipertensión, disminución del nivel de ka, insuficiencia adrenocortical Trastornos del esqueleto muscular y del tejido conectivo: hinchazón de las articulaciones, hinchazón molestias musculares
Trastorno general: edema
Trastornos cardíacos: sofocos, hipertensión, arritmias, dolor torácico, insuficiencia cardíaca
Trastornos GIT: diarrea, dispepsia
Infecciones e infestaciones: ITU
Trastorno pulmonar: tos
Renal: frecuencia urinaria, nocturia
Lesiones: fracturas.

Sobredosis

Zecyte 500mg tableta no tiene antídoto esencial. Si se produce una sobredosis, finalice el tratamiento con el medicamento y brinde medidas de apoyo generales, como el control de las arritmias y la insuficiencia cardíaca, y evalúe la función hepática.

DETALLES DE CONTACTO

Teléfono: 9987711567

Correo electrónico: applepharmaceutical@gmail.com

Correo electrónico: info@myapplepharma.com

Sitio web: https://myapplepharma.com/zecyte-500mg.php

https://myapplepharma.com/abiraterone.php

Abirapro 500mg |Abiraterone acetate | Apple Pharmaceuticals

Abiraterone is sold under brand name Abirapro 500mg.
Abirapro 500mg is belongs to type of anti-cancer medication that will act by decline the androgen production in the body.
Androgen is a male hormone that can maintained the tumor cell in prostate glands.
This drug is given by co administration with prednisolone, a steroid which reduce the liability of side effects produced by Abiraterone.

**Abirapro 500mg , Abirapro 500mg tablet**

DOSAGE

The prescribed dose of Abirapro is initial as 4 tablets given orally once daily.

The drug Abirapro administrated combination with 5mg prednisolone twice daily in empty stomach.

Abirapro 500mg tablet given on an empty stomach.
Food should not be taken for at least 2 hours before and at least 1 hour after the dose of Abirapro 500mg tablet is taken.
Swallowed whole with water.
Chew the tablets or Do not crush

MECHANISM OF ACTION

Androgens are balance the production of malignant in prostate.
Abirapro 500mg belongs to anti androgen drugs, that causes to suppress the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is involving in androgen conglomerate.
Reduce the serum testosterone level.
Declined the tumor cell occurred.

PHARMACOKINETICS

Absorption:

Time to maximum plasma concentration of Abirapro 500mg tablet takes 12 hours.

Distribution:

Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.

Metabolism:

The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.

Excretion:

The drug mainly excreted in 88% feces and 5% in urine
Half-life of tablet Abirapro 500mg is 12 ± 5 hours.

SAFETY AND WARNING

Any allergy, serious liver problem or pregnant in patient, Abirapro 500mg therapy should be stopped Avoid taking of other medications, i.e. prescription, over-the-counter, vitamins, herbal remedies, etc. be sure to inform the doctors before the treatment.
Do not take Aspirin administrated and products containing aspirin till doctor particularly allow the drug.

DRUG INTERACTION

Interaction of Abirapro 500mg tablet with dextromethorphan will raises the Cmax and AUC of dextromethorphan Interaction Abirapro 500mg with strong CYP3A inhibitors or inducers, concomitant use with caution because pharmacokinetics is not evaluated.

STORAGE

The drug stored at 15℃-30℃ Keep the drug in dry place.

MISSED DOSE

If patient missed the dose of Abirapro 500mg, that missed dose will be skipped and follow the regular dosing schedule.

SIDE EFFECTS

Common effects:Fatigue, Arthralgia, Hypertension, Nausea, edema, Hypokalemia, Diarrhea, vomiting, Cough, headache, Glucocorticoid deficiency, Mineral corticoid deficiency, Hepatotoxicity, Hypertension, Decrease in ka level, Adrenocortical insufficiency Muscular skeletal and Connective tissue disorders: Joint swelling, discomfort, muscle discomfort
General Disorder: Edema
Cardiac disorders: Hot flush, hypertension, arrhythmias, chest pain, cardiac failure
GIT disorders: Diarrhea, dyspepsia
Infections and Infestation: UTI
Pulmonary disorder: Cough
Renal: Urinary frequency, nocturia
Injuries: Fractures.

OVERDOSAGE

Abirapro 500mg tablet has no essential antidote, If overdose occurs end treatment with the drug and give general supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.

CONTACT DETAILS

Phone : 9987711567

Email : applepharmaceutical@gmail.com

Email : info@myapplepharma.com

Website :https://myapplepharma.com/abirapro-500mg.php

https://myapplepharma.com/abiraterone.php